Exactech Investor Update

Helping surgeons worldwide make patients more mobile

Q2 2017
 Investment Highlights

Targeting $47 billion Consistent long term Broad product portfolio Robust product pipeline
global biomedical device growth
market of innovative products expanding companys
2x as fast as overall
market market

Highly experienced Growing sales Proven track record

orthopaedic management organization of creating long-term
team profitable growth
with increasing rep
productivity

2
 Our Strategy

CUSTOMER INTIMACY

Innovation Channel
Development

Operational Excellence

3
 Our Story

Surgeon founded Innovation to improve Surgeon input driven Collaborative relationship Financial stability
patient outcomes with
sales force

4
 A proven track record of growth
$268M

2010
Vertical Supply 250
Acquisitions

200
1998

2008
Launched Internal Manufacturing French Distributor

REVENUE IN MILLIONS
Acquisition

Launching Vantage 150

2017
Ankle & Truliant Knee
2005 Equinoxe Shoulder Systems
Launch
100

2016
Launched Three
1994

First Knee Implant Revision Systems

Sales
50
Launch of ExactechGPS

2014
CAS Technology
Acquisition
0

YEAR 1985 1990 1994 1998 2002 2006 2010 2014 2017

5
 Targeting Highly Attractive Markets

Extremities Knee Hip Biologics

$2.0 Billion $8.5 Billion $7.0 Billion $4.9 Billion

Sales Sales Sales Sales

8% Growth Rate 4% Growth Rate 2% Growth Rate 3% Growth Rate

Source: OrthoWorld Orthopaedic Industry Annual Report April 2016 and company estimates

6
 Broad Portfolio of Innovative Products
2016 Sales by Segment ($ millions)

OTHER
$27.8
ExactechGPS KNEE HIP BIOLOGICS
EXTREMITIES
$100.3
HIP
$46.7
11%

19% 40%
EXTREMITIES ANKLE CEMENT/SPACERS

30%
KNEE
$76.2

2016 sales by segment based on 2016 SEC 10-K excluding divested spine business

7
Extremities
Equinoxe Platform Shoulder
redefining intra-operative
flexibility, solving clinical
challenges surgeons face.

Primary, Fracture, Reverse

Bone conserving glenoid options
Revision, Salvage and Tumor
solutions
Pipeline of strong clinical publications
ExactechGPS Computer Assisted
Surgery System launching 2H17
Preserve Short Stem launching 2H17
8
 Extremities
VantageTM Ankle System
Developed by world-class team of
design surgeons. Full launch in 2017.

9
 Knee
Comprehensive total knee system
with excellent clinical results.

40-year evolved design

Multiple constraint options for primary &
revision knees with NCM poly
Exactech GPS - Computer Assisted
Surgery System
Optetrak Logic CC revision

10
 Knee
Truliant high performance,
comprehensive system addresses primary
and revision knee replacement.

Supports surgeon goals for reproducible

clinical outcomes
Wide array of options for improved
versatility
Modified implant design to accommodate
various patient anatomy
Intuitive instrumentation with visual,
audible and tactile feedback for
intraoperative adjustability
Expanded Exactech GPS computer-
assisted surgery applications
Clinical introduction in 2H17 11
 Addressing the major Primary, Fracture, Revision

Hip philosophies of THA Tapered Wedge and Neck Preserving Stem designs
Direct Anterior Approach instrumentation
Acetabular cup with InteGrip technology
Alteon Monobloc Revision System

12
ExactechGPS Surgeon maintains operating control
Reproducible outcomes - Real-time feedback
Surgeon controlled, computer-assisted technology for Competitive marketing edge for hospitals
reproducibility in total joint arthroplasty. Applications for shoulder, primary and revision knee

13
 Biologics
Innovative, clinically effective
biomaterials

Optecure Allograft DBM products

Accelerate Cell Therapy
OssilixTM Calcium Phosphate Cement
ReveilleTM Cartilage Processor

14
Cement, Spacer
and Implant
Removal
Safety, simplicity and efficacy

Cemex bone cement

InterSpace preformed hip, knee and
shoulder spacers with High Release
technology
AcuDriver Automated Osteotome
System

15
Exactech Manufacturing

Lean initiatives in
Manufacturing 65% Internal manufacturing and
in U.S. Implant Mfg entire company.

16
 Our Reach

OUS
US
Network of independent
Network of independent distributors and wholly-
sales agencies (35+) owned subsidiaries
Independent sales Direct operations in: UK,
representatives (300+) Spain, Germany, France,
Japan, China, Australia
Managed by corporate
regional vice presidents

MANUFACTURING & DISTRIBUTORS GLOBAL

HEADQUARTERS OFFICES/SUBSIDIARIES

17
 Financial Trends
1.40
280 Earnings Per Share
Revenues ($ Mil) 269
257 1.30

248
242 1.18 1.18
237 1.20
224 1.12

220 1.04

1.00 0.96

160 0.80
12 13 14 15 16 17G 12 13 14 15 16* 17G

FY Guidance $267-271MM; +6-7% Proforma* FY17 Guidance $1.27-1.31

18 * Non-GAAP Revenue Growth and Diluted EPS Estimates excluding impact

of impairment/restructuring announced 4Q16
 Summary Financial Data

$ and shares in millions Dec-16 Jun-17

Cash $13.1 $8.9

Debt $20.0 $14.0

Shareholders Equity $234.2 $246.8

Common Shares Outstanding (1) 14.5

Market Value (2) $406.5

(1) Per 7.27.17 2Q17 Earnings Release

(2) Based on Market Closing Price $28.40 8.7.17
19
Why Exactech?

Understanding of market needs and

opportunities

Major new product introductions

Sales channel opportunities

Proven financial performance and

corporate stability

20
 Thank you.

This presentation contains various forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 which represent the companys expectations or beliefs concerning future events. These forward looking
statements are further qualified by important factors that could cause actual results to differ materially from those in the forward looking
statements. These factors include the effect of competitive pricing, the companys dependence on the ability of third party manufacturers to produce
components on a basis which is cost-effective to the company, market acceptance of the companys products and the effects of government
regulation, including without limitation an ongoing investigation by the U.S. Department of Justice of various practices within the orthopaedic
industry, as well as other risks and uncertainties including those described in the companys filings with the Securities and Exchange Commission.
You should carefully consider these risks before making a decision to invest in our securities. Results actually achieved may differ materially from
expected results included in these statements.